BrainsWay Announces Positive OCD Coverage Policy from Blue Cross Blue Shield® (BCBS) Licensee Highmark BCBS for Deep TMS™
21 juin 2022 08h00 HE
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, June 21, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Reports First Quarter 2022 Financial Results and Operational Highlights
11 mai 2022 07h30 HE
|
BrainsWay
Revenue Growth of 30% Year-over-Year in Q1 2022 Conference call to be held today, May 11, 2022, at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, May 11, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd....
BrainsWay Appoints Eric Hirt as Vice President of U.S. Sales
09 mai 2022 08h00 HE
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, May 09, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay to Present Expanded Post-Marketing Clinical Research for Major Depressive Disorder at Clinical TMS Society
04 mai 2022 08h00 HE
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, May 04, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Launches #DontMissAnotherMoment Social Media Campaign to Promote Mental Health Awareness Month
02 mai 2022 08h46 HE
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, Israel, May 02, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive...
BrainsWay to Report First Quarter Financial Results on May 11, 2022
27 avr. 2022 08h00 HE
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, April 27, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Appoints Dr. Joachim Seidel as Vice President of Corporate Development and Strategy
28 mars 2022 08h00 HE
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, March 28, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay to Host Key Opinion Leader Webinar on Deep TMS™ Therapy for Treating Anxious Depression
15 mars 2022 08h00 HE
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, March 15, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay Reports Fourth Quarter and Full-Year 2021 Financial Results and Operational Highlights
09 mars 2022 07h30 HE
|
BrainsWay
Revenue Growth of 34% in 2021, with Record Quarterly and Annual Revenues Continued Progress in Expanding FDA Labeling for Deep TMS™ and Increasing Payor Coverage Conference call to be held today,...
BrainsWay to Present at the 32nd Annual Oppenheimer Healthcare Conference
01 mars 2022 08h00 HE
|
BrainsWay
BURLINGTON, Mass. and JERUSALEM, March 01, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...